A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

Trial Identifier: D8500C00001
Sponsor: AstraZeneca
Collaborator:
Biomedical Advanced Research and Development Authority (BARDA),
Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)
Start Date: September 2025
Primary Completion Date: January 2026
Study Completion Date: December 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Long Beach, CA, US, 90815
US, CA Rolling Hills Estates, CA, US, 90274
US, FL Hialeah, FL, US, 33012
US, GA Stockbridge, GA, US, 30281
US, IL Chicago, IL, US, 60640
US, KS Lenexa, KS, US, 66219
US, MO Kansas City, MO, US, 64114
US, NE Omaha, NE, US, 68134
US, NV Las Vegas, NV, US, 89119
US, OH Cincinnati, OH, US, 45212
US, OK Edmond, OK, US, 73013
US, SC North Charleston, SC, US, 29405
US, TX Austin, TX, US, 78745
US, UT West Jordan, UT, US, 84088